Leslie Cloud is a Neurology physician affiliated with Virginia Commonwealth University. OpenAlex indexes 51 publications with 1,104 citations (h-index 16); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1250 E Marshall St
Neurology
Richmond, VA 232985051
Telephone
804-828-5512Registry record last updated 12 Jul 2011.
Clinical trials
- Optimizing Vibrational Therapy to Improve Gait and Balance in Parkinson's Disease
Sponsor: Virginia Commonwealth University
- Vibrational Therapy to Improve Gait and Balance in Parkinson's Disease
Sponsor: Virginia Commonwealth University
- RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease
Sponsor: Virginia Commonwealth University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amneal Pharmaceuticals LLCProgram year20254 payments
- Takeda Pharmaceuticals U.S.A., Inc.Program year20252 payments
- Medtronic, Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
94.9%Aromatic Amino Acid Decarboxylation Inhibitor41%Carbidopa-Levodopa59%Carbidopa-Levodopa Er28%Rytary9%Carbidopa2%Carbidopa-Levodopa-Entacapone2%Duopa1%Part D<11 patientsBenzodiazepine6.3%Clonazepam88%Alprazolam12%Part D<11 patients+ 17 more classes in this area
Cardiovascular
2.4%Beta blocker2%Propranolol Hcl Er78%Propranolol Hcl22%Part D<11 patientsalpha-Adrenergic Agonist0.4%Midodrine Hcl100%Part D<11 patientsMusculoskeletal
0.9%gamma-Aminobutyric Acid-ergic Agonist0.9%Baclofen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2021–2024 per NIH RePORTER. The latest:
- SCH: Context-aware Freezing of Gait mitigation in real-world setting
Virginia Commonwealth University
FY2024$228,849R01NS120560 - SCH: Context-aware Freezing of Gait mitigation in real-world setting
Virginia Commonwealth University
FY2024$1R01NS120560 - SCH: Context-aware Freezing of Gait mitigation in real-world setting
Virginia Commonwealth University
FY2023$323,564R01NS120560
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Consensus expert recommendations for management of dysphagia during hospital admission in Parkinson's disease
Journal of Parkinson s Disease
2026 - Impact of Subthalamic Nucleus Deep Brain Stimulation on Gastrointestinal Symptoms and Gastric Emptying in Parkinson’s Disease: A Systematic Review and Meta-Analysis
Neuromodulation Technology at the Neural Interface
2025 - Efficacy of the iron‐chelating agent, deferiprone, in patients with Parkinson's disease: A systematic review and meta‐analysis
CNS Neuroscience & Therapeutics
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Jasmohan Bajaj, MD
Virginia Commonwealth University
Patrick Ching, MD, MPH
Virginia Commonwealth University
Bruce Rubin, MD
Virginia Commonwealth University
Arehzo Jahangiri, MD
Virginia Commonwealth University
Bruce Miller, MD
University of California, San Francisco (UCSF)
Brett Kissela, MD
Medical College of Wisconsin
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”